Infantile high-grade glioma with CLIP2-MET fusion mutation: a case report and therapeutic challenges
Authors:
- Jheremy Sebastian Reyes BarretoJBJheremy Sebastian Reyes Barreto
- Raul Fernando Vega AlvearRARaul Fernando Vega Alvear
- Juan Sebastian Aguirre PatiñoJPJuan Sebastian Aguirre Patiño
- Sofia Catalina Velasco SandovalSSSofia Catalina Velasco Sandoval
- Oscar Eduardo González FigueredoOFOscar Eduardo González Figueredo
Open Access
- 30 November 2025
- journal article
- Published by Asociacion Colombiana de Hematologia y Oncologia in Revista Colombiana de Hematología y Oncología
- Vol. 12 (2) , 99-106
Abstract
Introduction: Infantile high-grade gliomas are rare malignancies of the central nervous system (CNS) in children. Despite advancements, significant challenges remain in their treatment. A better understanding of their molecular biology may provide new therapeutic options. Clinical case: We report the case of a 30-month-old female diagnosed with an infantile high-grade glioma. Following urgent surgical resection, molecular analysis via a fusion panel identified a CLIP2-MET fusion mutation. This finding suggested potential treatment with crizotinib, a targeted therapy. However, several barriers delayed treatment initiation, including the lack of approval for crizotinib use in CNS tumors in Colombia and concerns about interactions with anticonvulsant therapy. Despite a brief period of clinical stability after initiating treatment, the patient unfortunately succumbed to the disease. Conclusion: Infantile high-grade gliomas pose significant therapeutic challenges, but identifying specific gene fusions, such as CLIP2-MET, may open new avenues for targeted therapy. This case underscores the need for regulatory adaptations to facilitate access to promising treatments when evidence supports their potential efficacy. To our knowledge, this is the first case in Colombia where an infantile glioma was treated with crizotinib, highlighting both the promise and the challenges of precision medicine in pediatric oncology.Keywords
This publication has 15 references indexed in Scilit:
- MET fusions are targetable genomic variants in the treatment of advanced malignanciesCell Communication and Signaling, 2024
- HGG-03. HIGH-GRADE GLIOMA IN YOUNG CHILDREN IS HISTOLOGICALLY, MOLECULARLY, AND CLINICALLY DIVERSE—RESULTS FROM THE SJYC07 TRIAL AND INSTITUTIONAL EXPERIENCENeuro-Oncology, 2023
- The oncogenic fusion landscape in pediatric CNS neoplasmsActa Neuropathologica, 2022
- Infant High-Grade Gliomas Comprise Multiple Subgroups Characterized by Novel Targetable Gene Fusions and Favorable OutcomesCancer Discovery, 2020
- A glioneuronal tumor with CLIP2-MET fusionnpj Genomic Medicine, 2020
- The Power of Human Cancer Genetics as Revealed by Low-Grade GliomasAnnual Review of Genetics, 2019
- Alterations in ALK/ROS1/NTRK/MET drive a group of infantile hemispheric gliomasNature Communications, 2019
- Gene Fusion in Malignant Glioma: An Emerging Target for Next-Generation Personalized TreatmentTranslational Oncology, 2018
- Safety and activity of crizotinib for paediatric patients with refractory solid tumours or anaplastic large-cell lymphoma: a Children's Oncology Group phase 1 consortium studyThe Lancet Oncology, 2013
- Gain of chromosome band 7q11 in papillary thyroid carcinomas of young patients is associated with exposure to low-dose irradiationProceedings of the National Academy of Sciences, 2011